SecProbe.io

October 9, 2013

Via E -mail
Peter Langecker, M.D., Ph.D.
Chief Executive Officer
OXiGENE, Inc.
701 Gateway Blvd., Suite 210
South San Francisco, California 94080

Re: OXiGENE, Inc.
  Registration Statement on Form S-3
Filed  October 2, 2013
  File No.  333-191531

Dear Dr. Langecker :

We have limited our review of your registration statement to the issue  we have addressed
in our comment .

Please respond to this letter by amending your registration statement and providing the
requested information .  Where  you do not believe our comment applies  to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.

After revi ewing any amendment to your registration statement and the information you
provide in response to this comment , we may have  additional comments.

General

1. We note that you have a separate  registration statement on Form S -1, filed August 8,
2013 , that is currently being reviewed by the staff .  Please be advised that we will not be
in a positio n to accelerate the effectiveness of your registration statement on Form S -3
until our revi ew of your registration statement on Form S -1 has been completed .

We urge all persons who are responsible for the accuracy and adequacy of the disclosu re
in the filing to be certain that the filing includes the information the Securities Act of 193 3 and
all applicable Securities  Act rules require.   Since the company and its management are in
possession of all facts relating to a company’s disclosure, the y are responsible for the accuracy
and adequacy of the disclosures they have made.

Notwithstanding our comments, in the event you request acceleration of the effective date
of the pending registration statement please provide a written statement from th e company
acknowledging that:

Peter Langecker , M.D., Ph.D.
OXiGENE, Inc.
October 9, 2013
Page 2

 should the Commission or the staff, acting pursuant to delegated authority, declare the
filing effective, it does not foreclose the Commission from taking any action with respect
to the filing;

 the action of the Commission or the staff, acting pursuant to delegated authority, in
declaring the filing effective, does not relieve the company from its full responsibility for
the adequacy and accuracy of the disclosure in the filing; and

 the company  may not assert staff comments and the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.

Please refer to Rules 460 and 461 regarding requests for  acceleration .  We will consider a
written request for acceleration of the effective date of the registration statement as confirmation
of the fact that those requesting acceleration are aware of their respective responsibilities under
the Securities Act of 1933 and the Securities Exchange Act of 1934 as they relate to the proposed
public offering of the securities specified in the above registration statement.  Please allow
adequate time  for us to review any amendment prior to the requested effective date of  the
registration statement.

Please contact Matthew Jones at (202) 551 -3786 or me at (202) 551 -3715 with any other
questions.

Sincerely,

 /s/ Daniel  Greenspan  for

Jeffrey P. Riedler
Assistant Director

cc:  Megan Gates
 Mintz, Levin, Cohn, Ferris  Glovsky and Popeo, P.C .
 One Financial Center
 Boston, MA 02111